Logo do repositório
 
Publicação

Genetic diversity and antiretroviral resistance in HIV-1-infected patients newly diagnosed in Cabo Verde

datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorLeal, Silvânia da Veiga
dc.contributor.authorPimentel, Victor
dc.contributor.authorGonçalves, Paloma
dc.contributor.authorAraújo, Isabel Inês Monteiro de Pina
dc.contributor.authorParreira, Ricardo
dc.contributor.authorTaveira, Nuno
dc.contributor.authorPingarilho, Marta
dc.contributor.authorAbecasis, Ana B.
dc.date.accessioned2026-04-01T09:55:01Z
dc.date.available2026-04-01T09:55:01Z
dc.date.issued2024-12
dc.description.abstractThe high genetic variability of HIV-1 and the emergence of transmitted drug resistance (TDR) can impact treatment efficacy. In this study, we investigated the prevalent HIV-1 genotypes and drug-resistance-associated mutations in drug-naïve HIV-1 individuals in Cabo Verde. The study, conducted between 2018 and 2019, included drug-naïve HIV-1 individuals from the São Vicente, Boa Vista, Fogo, and Santiago islands. The HIV-1 pol gene was sequenced using Sanger sequencing. TDR was identified using the Stanford Calibrated Population Resistance tool, and resistance levels to different drugs were interpreted with the Stanford HIV database. The genetic diversity of HIV-1 was determined through phylogenetic analysis, and epidemiological and behavioural data were collected via questionnaires. Of the 73 participants, the majority were male (52.1%). The CRF02_AG recombinant form predominated (41.1%), followed by subtype G (37.0%). The overall prevalence of TDR was 9.6%. Nucleoside Reverse Transcriptase Inhibitor (NRTI) mutations occurred in 2.7% of individuals, while Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) mutations occurred in 9.6%. The most prevalent mutations were K103N (5.5%) and M184V (2.7%). No protease- or integrase-associated mutations were found. The high levels of resistance to NNRTIs found demonstrate the need for surveillance of resistance mutations to ensure the efficacy and durability of the current therapeutic regimen, which includes Dolutegravir.eng
dc.identifier.citationLeal SDV, Pimentel V, Gonçalves P, Monteiro de Pina Araújo II, Parreira R, Taveira N, Pingarilho M, Abecasis AB. Genetic Diversity and Antiretroviral Resistance in HIV-1-Infected Patients Newly Diagnosed in Cabo Verde. Viruses. 2024; 16(12):1953. https://doi.org/10.3390/v16121953
dc.identifier.doi10.3390/v16121953
dc.identifier.issn1999-4915
dc.identifier.urihttp://hdl.handle.net/10400.26/62560
dc.language.isoeng
dc.peerreviewedyes
dc.publisherMDPI
dc.relation.hasversionhttps://doi.org/10.3390/v16121953
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjecttransmitted drug resistance
dc.subjectHIV-1 subtypes
dc.subjectgenetic diversity
dc.subjectgenomic surveillance
dc.subjectCabo Verde
dc.titleGenetic diversity and antiretroviral resistance in HIV-1-infected patients newly diagnosed in Cabo Verdeeng
dc.typecontribution to journal
dspace.entity.typePublication
oaire.citation.issue12
oaire.citation.titleViruses
oaire.citation.volume16
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
Artigo_NTaveira_2024_03.pdf
Tamanho:
2.25 MB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.85 KB
Formato:
Item-specific license agreed upon to submission
Descrição: